On June 2, CARsgen Therapeutics-B declined 5.14% in regular trading, trading at HK$16.41/share, with trading volume of HK$31.89 million. The stock continued its downward trajectory as the dilutive impact of a recently completed discounted share placement and ongoing institutional selling weighed on market sentiment.

The company completed a top-up placement of 23.7 million shares at HK$19.84 per share on May 26, raising net proceeds of approximately HK$462 million. Following the placement, total issued shares increased to approximately 595 million. The funds raised are earmarked with 70% allocated to global clinical development of innovative therapies, 15% to R&D and production facilities, and 15% to working capital. The placement price represented a discount to the prevailing market price, and the resulting dilution has persistently suppressed the stock since completion.

Meanwhile, the Hong Kong-listed biotech sector broadly weakened, with 3SBIO down 7.45%, SKB Bio down 4.23%, Akeso down 3.36%, BeiGene down 2.22%, and Innovent Bio down 2.16%, reflecting broader valuation compression across the industry that further exacerbated individual stock corrections.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)